Myelofibrosis surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}}{{AE}}{{SR}} | {{CMG}}{{AE}}{{SR}}{{Sab}} | ||
==Overview== | ==Overview== | ||
| Line 18: | Line 18: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Medicine]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Neurosurgery]] | [[Category:Neurosurgery]] | ||
[[Category:Up-To-Date]] | |||
Latest revision as of 22:50, 29 July 2020
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis surgery On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]Sabawoon Mirwais, M.B.B.S, M.D.[3]
Overview
Surgery is not the first-line treatment option for patients with myelofibrosis. Splenectomy is usually reserved for patients with massive splenomegaly unresponsive to conservative treatment. The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.
Surgery
Splenectomy
- Surgery is not the first-line treatment option for patients with myelofibrosis.
- Splenectomy is usually reserved for patients with massive splenomegaly unresponsive to conservative treatment.[1][2][3]
- It is associated with postoperative morbidity rate of 15-30% and a mortality rate of 10%.
Allogeneic stem cell transplantation
The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.[4]
References
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
- ↑ Tefferi A (December 2018). "Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management". Am. J. Hematol. 93 (12): 1551–1560. doi:10.1002/ajh.25230. PMID 30039550.
- ↑ Pardanani A, Tefferi A (August 2018). "How I treat myelofibrosis after failure of JAK inhibitors". Blood. 132 (5): 492–500. doi:10.1182/blood-2018-02-785923. PMID 29866811.
- ↑ Cervantes F (2005). "Modern management of myelofibrosis". Br. J. Haematol. 128 (5): 583–92. doi:10.1111/j.1365-2141.2004.05301.x. PMID 15725078. Unknown parameter
|month=ignored (help)